[go: up one dir, main page]

CA2692493A1 - Nano-eponges a base de cyclodextrine comme vehicule pour medicaments anti-tumoraux - Google Patents

Nano-eponges a base de cyclodextrine comme vehicule pour medicaments anti-tumoraux Download PDF

Info

Publication number
CA2692493A1
CA2692493A1 CA 2692493 CA2692493A CA2692493A1 CA 2692493 A1 CA2692493 A1 CA 2692493A1 CA 2692493 CA2692493 CA 2692493 CA 2692493 A CA2692493 A CA 2692493A CA 2692493 A1 CA2692493 A1 CA 2692493A1
Authority
CA
Canada
Prior art keywords
paclitaxel
nanosponges
complexes
cyclodextrin
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692493
Other languages
English (en)
Inventor
Francesco Trotta
Vander Tumiatti
Roberta Cavalli
Carlo Maria Roggero
Barbara Mognetti
Giovanni Nicolao Berta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEA MARCONI TECHNOLOGIES DI VANDER TUMIATTI Sas
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2692493A1 publication Critical patent/CA2692493A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/02—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by the reacting monomers or modifying agents during the preparation or modification of macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2201/00—Foams characterised by the foaming process
    • C08J2201/02—Foams characterised by the foaming process characterised by mechanical pre- or post-treatments
    • C08J2201/026—Crosslinking before of after foaming
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2205/00—Foams characterised by their properties
    • C08J2205/04—Foams characterised by their properties characterised by the foam pores
    • C08J2205/042—Nanopores, i.e. the average diameter being smaller than 0,1 micrometer
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00—Foams characterised by their intended use
    • C08J2207/10—Medical applications, e.g. biocompatible scaffolds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2692493 2007-07-04 2008-06-27 Nano-eponges a base de cyclodextrine comme vehicule pour medicaments anti-tumoraux Abandoned CA2692493A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001321A ITMI20071321A1 (it) 2007-07-04 2007-07-04 Nanospugne a base di ciclodestrine come veicolo per farmaci antitumorali
ITMI2007A001321 2007-07-04
PCT/EP2008/005290 WO2009003656A1 (fr) 2007-07-04 2008-06-27 Nano-éponges à base de cyclodextrine comme véhicule pour médicaments anti-tumoraux

Publications (1)

Publication Number Publication Date
CA2692493A1 true CA2692493A1 (fr) 2009-01-08

Family

ID=39863047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692493 Abandoned CA2692493A1 (fr) 2007-07-04 2008-06-27 Nano-eponges a base de cyclodextrine comme vehicule pour medicaments anti-tumoraux

Country Status (5)

Country Link
EP (1) EP2175847A1 (fr)
JP (1) JP2010531827A (fr)
CA (1) CA2692493A1 (fr)
IT (1) ITMI20071321A1 (fr)
WO (1) WO2009003656A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20110372A1 (it) 2011-04-28 2012-10-29 Univ Degli Studi Torino Metodo per la preparazione di nanospugne di destrine
CN102671214B (zh) * 2012-05-04 2013-05-15 华东师范大学 一种还原降解释药的喜树碱超分子胶束前药及制备方法和应用
ITBO20120710A1 (it) * 2012-12-28 2014-06-29 Univ Degli Studi Torino Sistema di veicolazione per l'insulina
JP6276431B2 (ja) * 2014-07-07 2018-02-07 ロケット イタリア エス．ピー．エイ． 有機化合物をカプセル封入するための、マルトデキストリンをベースとするポリマー

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4958015A (en) * 1988-09-30 1990-09-18 Uop Preparation of crosslinked cyclodextrin resins with enhanced porosity
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US20010008222A1 (en) * 1998-12-23 2001-07-19 Min Ma Cyclodextrin polymer separation materials
WO2003085002A1 (fr) * 2002-04-10 2003-10-16 Sea Marconi Technologies Di W. Tumiatti S.A.S Polymeres reticules a base de cyclodextrines destines a eliminer des agents polluants
CN1717209A (zh) * 2002-10-09 2006-01-04 植入疗法公司 以环糊精为基础的材料、其相关的组合物和用途
EP1632503A1 (fr) * 2004-06-25 2006-03-08 Sea Marconi Technologies Di Wander Tumiatti S.A.S. Synthèse par ultrasons d'éponges à base de cyclodextrines dont la dimension des pores est de l'ordre du nanomètre
ES2310948B2 (es) * 2005-02-25 2009-09-16 Universidade De Santiago De Compostela Procedimiento de obtencion de hidrogeles de ciclodextrinas con glicidileteres, las composiciones obtenidas y sus aplicaciones.

Also Published As

Publication number Publication date
EP2175847A1 (fr) 2010-04-21
WO2009003656A1 (fr) 2009-01-08
JP2010531827A (ja) 2010-09-30
ITMI20071321A1 (it) 2009-01-05

Similar Documents

Publication Publication Date Title
dos Santos Lima et al. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects
Swaminathan et al. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity
Vijayakumar et al. Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines
Sharma et al. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins
Zhang et al. Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: Preparation, characterization, cellular uptake and bioavailability evaluation
JP5369137B2 (ja) 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
Hu et al. Redox and pH dual responsive poly (amidoamine) dendrimer-poly (ethylene glycol) conjugates for intracellular delivery of doxorubicin
Van et al. Synthesis, characterization, and biological evaluation of poly (L-γ-glutamyl-glutamine)-paclitaxel nanoconjugate
US5684169A (en) Cyclodextrin inclusion complex of taxol, and method for its production and its use
CA2468556A1 (fr) Polymere amphiphile biocompatible greffe avec de la cyclodextrine et methodes de production et d'utilisation
JP4757633B2 (ja) 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物
Liu et al. Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel
HU213200B (en) The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
CN113264906A (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
JP5103476B2 (ja) シクロデキストリン・ドセタキセルの包接体を含む薬物組成物及びその製造方法
CA2123946C (fr) Produit d'inclusion du paclitaxel dans la cyclodextrine, methode de production et utilisation
CA2692493A1 (fr) Nano-eponges a base de cyclodextrine comme vehicule pour medicaments anti-tumoraux
EP2061458A1 (fr) Compositions de topiramate et procédés de leur utilisation
De Melo et al. In silico and in vitro study of epiisopiloturine/hydroxypropyl-β-cyclodextrin inclusion complexes obtained by different methods
CN108524951A (zh) 一种具有肝肿瘤靶向作用的索拉菲尼纳米制剂
JP5774013B2 (ja) シクロデキストリンのデオキシポドフィロトキシン包接錯体、その調製法、および癌治療への使用
EP2167031A2 (fr) Polymères hyperramifiés basés sur des cyclodextrines et poly(amidoamines) utilisés dans la libération régulée de médicaments insolubles
Kashapov et al. Solubility and biological activity enhancement of the highly lipophilic viridicatins via interaction with cyclodextrins
KR101039095B1 (ko) ｐＨ 민감성을 갖는 약물전달용 생체적합성 나노복합체 및 이의 제조방법
CN106860875B (zh) 抗肿瘤的pH敏感和非pH敏感的葡聚糖-聚乳酸-聚乙二醇纳米载药体系的制备方法

Legal Events

Date Code Title Description
FZDE Dead